CorFlow Therapeutics is incorporated in Baar, Switzerland, and closed the Seed financing rounds in September 2018 raising a total of CHF 9.4M (USD 9.7M). The rounds were supported by experienced cardiovascular medical device investors and interventional cardiologists. These investors have over decades financed successful medical device companies such as CoreValve and CardiAQ.

CorFlow plans successive investment rounds starting Q2/19. The company invites investors who want to support a potential disruptive technology to diagnose and treat microvascular obstruction to participate in these upcoming rounds.

Feel free to contact CorFlow’s CEO, Jon H. Hoem,

+41 79 606 2 902

for further details on the upcoming financing rounds.